According to a new study published in the Feb. 13 online edition of The Lancet, it was found that when women used hormone replacement therapy for less than five years after menopause, the risk of ovarian cancer increased by about 40 percent.

“We have evidence, proof, that there is a small but real excess risk of cancer of the ovaries with hormone therapy use,” said study researcher Sir Richard Peto, professor of medical statistics and epidemiology at the University of Oxford, in England.

Peto said the increased risk was significant from a statistical standpoint but emphasized that the risk is a small one. It would mean that for women who take hormone therapy for five years from around age 50, one extra ovarian cancer diagnosis for every 1,000 users would be expected, and one extra ovarian cancer death for every 1,700 users, the study found. (Read more here >>)

Dr. David Lim provides regulatory consulting and training services for medical products regulated by the US FDA, an Agency under the US Department of Health and Human Services (DHHS).

Hormone Therapy May Be Tied to Increased Ovarian Cancer
Tagged on: